Clinical testing
The National Measurement Institute (NMI) produce reference materials (RMs) in accordance with our accreditation from National Association of Testing Authorities (NATA) to ISO 17034:2016(E) General requirements for the competence of reference materials producers. We supply RMs with product information sheets and safety data sheets.
Displaying 1 - 116 of 116| Category | Description | NMI Reference | Unit of issue in mg | Domestic Cost (A$ excl GST) | International cost (A$) | Certificate |
|---|---|---|---|---|---|---|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Testosterone |
M914 | 10 | 110 | 154 |
 M914c.2019.01 (Bottled 190618)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Testosterone glucuronic acid |
D507 | 1 | 141 | 198 |
D507d.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Testosterone sulfate (Et3N salt) |
D508 | 1 | 110 | 154 |
D508.2020.01 (Ampouled 110616)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Epitestosterone |
D547 | 1 | 110 | 154 |
D547.2020.01 (Ampouled 120918)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Epitestosterone sulfate triethylammonium salt |
D605 | 1 | 110 | 154 |
D605.2019.02 (Ampouled 090429)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Dihydrotestosterone |
D680 | 10 | 110 | 154 |
D680.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Dihydrotestosterone glucuronide free acid |
S006 | 1 | 141 | 198 |
S006.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Dihydrotestosterone sulfate |
D609 | 1 | 110 | 154 |
D609.2020.01 (Ampouled 101109)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Androsterone |
D550 | 10 | 110 | 154 |
D550c.2019.01 (Bottled 180307)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Androsterone glucuronide |
D572 | 1 | 141 | 198 |
D572b.2021.01 (Ampouled 190117)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Androsterone sulfate (Na+ salt) |
D610 | 1 | 110 | 154 |
D610b.2017.02 (Ampouled 100315)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Etiocholanolone |
D551 | 1 | 110 | 154 |
D551c.2019.02 (Ampouled 190221)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Etiocholanolone glucuronide (Na+ salt) |
D607 | 1 | 110 | 154 |
D607.2020.01 (Ampouled 090218)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Etiocholanolone sulfate |
D608 | 1 | 110 | 154 |
D608.2020.01 (Ampouled 130508)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Androstane-3α,17β-diol |
D634 | 1 | 110 | 154 |
D634b.2018.03 (Ampouled 180920)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Androstane-3α,17β-diol-17-β-glucuronic acid |
S002 | 1 | 110 | 154 |
S002.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Androstane-3α,17β-diol-3-β-glucuronic acid |
S004 | 1 | 141 | 198 |
S004.2017.02
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5α-Androstane-3β, 17β-diol |
D635 | 1 | 141 | 198 |
D635.2019.02 (Ampouled 100816)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5β-Androstane-3α,17β-diol |
D636 | 1 | 110 | 154 |
D636.2018.03 (Ampouled 181108)
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5β-Androstane-3α, 17β-diol-3-O-β-glucuronic acid |
S003 | 1 | 141 | 198 |
S003b.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
5β-Androstane-3β,17β-diol |
D637 | 1 | 141 | 198 |
D637.2021.01 (Ampouled 100809)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-Testosterone |
D546 | 1 | 141 | 198 |
D546.2019.01 (Ampouled 190926)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
16,16,17-d3-Testosterone glucuronide (sodium salt) |
S036 | 1 | 110 | 154 |
S036.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
16,16,17-d3-Testosterone sulfate |
D506 | 1 | 141 | 198 |
D506b.2020.01 (Ampouled 200701)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
19-d3-Testosterone |
D644 | 1 | 207 | 290 |
D644.2016.02 (Ampouled 071105)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-Epitestosterone |
D548 | 1 | 141 | 198 |
D548.2020.03 (Ampouled 170323)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d4-Epitestosterone |
S001 | 1 | 141 | 198 |
S001.2018.02 (Ampouled 170706)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-Epitestosterone sulfate |
D591 | 1 | 141 | 198 |
D591.2017.02 (Ampouled 090521)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-5α-Dihydrotestosterone |
D552 | 1 | 141 | 198 |
D552.2021.01 (Ampouled 110404)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-5α-Dihydrotestosterone glucuronide free acid |
D573 | 1 | 141 | 198 |
D573b.2020.01 (Ampouled 201026)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-5α-Dihydrotestosterone sulfate |
D590 | 1 | 141 | 198 |
D590.2016.02
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d4-Androsterone |
D549 | 1 | 141 | 198 |
D549.2020.01 (Ampouled 141014)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d4-Androsterone glucuronic acid |
D829 | 1 (ampoule) | 141 | 198 |
D829e.2016.01 (Ampouled 160331)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d4-Androsterone sulfate |
D587 | 1 | 141 | 198 |
D587.2016.02 (Ampouled 101014)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d5-Etiocholanolone |
D528 | 1 | 141 | 198 |
D528c.2020.01 (Ampouled 200102)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d5-Etiocholanolone sulfate (NEt3 salt) |
D606 | 1 | 141 | 198 |
D606.2019.02 (Ampouled 100716)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-5α-Androstane-3α,17β-diol |
D593 | 1 | 141 | 198 |
D593.2020.01 (Ampouled 170316)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d3-5α-Androstane-3β,17β-diol |
D594 | 1 | 141 | 198 |
D594.2020.01 (Ampouled 081127)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d5-5β-Androstane-3α,17β-diol |
D580 | 1 | 141 | 198 |
D580.2020.01 (Ampouled 200305)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
d5-5β-Androstane-3β,17β-diol |
S014 | 1 | 110 | 154 |
S014.2020.01 (Ampouled 160630)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
5α-Androstane-3β,17β-diol-3-β-glucuronic acid |
D678 | 1 | 141 | 198 |
D678b.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
5α-Androstane-3β-ol-17-one-3-glucuronide Na+ salt |
S031 | 1 | 110 | 154 |
S031.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of testosterone and metabolites |
17α-Hydroxyprogesterone |
S041 | 20 | 110 | 154 |
S041.2021.01 (Bottled 201021)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
Nandrolone |
S038 | 10 | 110 | 154 |
S038.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
17β-Nandrolone glucuronide (K+ salt) |
D861 | 1 | 207 | 290 |
D861.2017.04 (Ampouled 100805)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
Nandrolone sulfate, sodium salt |
D809 | 1 | 110 | 154 |
D809b.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
17α-Nandrolone |
D722 | 1 | 110 | 154 |
D722e.2020.01 (Ampouled 180621)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
Epinandrolone sulfate TEA salt |
D783 | 1 | 207 | 290 |
D783b.2020.01 (Bottled 190430)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
19-Norandrosterone |
D555 | 1 | 110 | 154 |
D555a.2017.03 (Ampouled 161020)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
19-Norandrosterone glucuronide (Na+ salt) |
D596 | 1 | 141 | 198 |
D596a.2018.02 (Ampouled 140821)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
19-Norandrosterone sulfate (Et3N salt) |
D841 | 1 | 110 | 154 |
D841b.2020.01 (Ampouled 110705)
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
19-Noretiocholanolone |
D554 | 1 | 110 | 154 |
D554.2019.02 (Ampouled 140717)
|
| Clinical testing›Ephedrine and related compounds |
(-)-Ephedrine hydrochloride |
M924 | 100 | 141 | 198 |
M924.2016.02
|
| Clinical testing›Endogenous steroids and metabolites›Nandrolone and metabolites |
19-Noretiocholanolone glucuronide (Na salt) |
D595 | 1 | 141 | 198 |
D595a.2019.01 (Ampouled 100322)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
d3-17β-Nandrolone |
D583 | 5 | 207 | 290 |
D583.2019.02 (Bottled 160913)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
d3-17β-Nandrolone sulfate (Et3N salt) |
D782 | 1 | 141 | 198 |
D782b.2020.01 (Ampouled 090107)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
13C2-17β-Nandrolone |
D679 | 5 | 171 | 240 |
D679.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
d4-19-Norandrosterone |
D584 | 1 | 141 | 198 |
D584c.2020.01 (Amouled 140731)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
d4-19-Norandrosterone glucuronide (Na+ salt)* |
D898 | 1 | 110 | 154 |
D898b.2020.01 (Ampouled 200213)
|
| Clinical testing›Endogenous steroids and metabolites›Deuterated internal standards of nandrolone and metabolites |
d4-19-Noretiocholanolone |
D742 | 1 | 141 | 198 |
D742.2018.02 (Ampouled 090319)
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-Amphetamine hydrochloride |
D736 | 50 | 141 | 198 |
D736
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-Amphetamine sulfate |
D420 | 50 | 110 | 154 |
D420d.2019.02 (Bottled 150423)
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
d-(+)-Amphetamine sulfate |
D961 | 50 | 141 | 198 |
D961.2019.01
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-4-Methylmethamphetamine hydrochloride |
D963 | 20 | 171 | 240 |
D963.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-Methamphetamine hydrochloride |
D816 | 50 | 141 | 198 |
D816g.2021.01 (Bottled 210413)
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
S-(+)-Methamphetamine hydrochloride |
D830 | 50 | 110 | 154 |
D830b.2020.01 (Bottled 170314)
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-3,4-Methylenedioxyamphetamine hydrochloride (MDA) |
D842 | 50 | 110 | 154 |
D842
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-N-Methyl-3,4-methylenedioxyamphetamine hydrochloride (MDMA) |
D792 | 50 | 141 | 198 |
D792f.2021.01 (Bottled 200707)
|
| Clinical testing›Cocaine and related compounds |
Benzoylecgonine tetrahydrate |
D745 | 50 | 141 | 198 |
D745
|
| Clinical testing›Cocaine and related compounds |
Cocaine base |
D826 | 50 | 141 | 198 |
D826b.2019.02 (Bottled 190814)
|
| Clinical testing›Cocaine and related compounds |
Cocaine hydrochloride |
D747 | 20 | 141 | 198 |
D747
|
| Clinical testing›Cocaine and related compounds |
Ecgonine hydrochloride |
D746 | 50 | 141 | 198 |
D746
|
| Clinical testing›Cocaine and related compounds |
Methyl ecgonine hydrochloride, monohydrate |
D452 | 10 | 171 | 240 |
D452c.2020.01 (Bottled 160414)
|
| Clinical testing›Ephedrine and related compounds |
(+)-Ephedrine hemihydrate |
M723 | 100 | 141 | 198 |
M723.2018.02
|
| Clinical testing›Opiates |
Methyl codeine |
D924 | 10 | 110 | 154 |
D924.2020.01
|
| Clinical testing›Ephedrine and related compounds |
dl-Norephedrine hydrochloride |
M296 | 100 | 110 | 154 |
M296.2019.01
|
| Clinical testing›Ephedrine and related compounds |
(+)-Norpseudoephedrine hydrochloride (Cathine) |
M297 | 50 | 110 | 154 |
M297.2020.01
|
| Clinical testing›Ephedrine and related compounds |
p-Hydroxyephedrine hydrochloride (Oxilifrine hydrochloride) |
D892 | 5 | 110 | 154 |
D892.2017.02 (Bottled 180418)
|
| Clinical testing›Ephedrine and related compounds |
(-)-Methylephedrine hydrochloride |
M243 | 20 | 110 | 154 |
M243b.2018.02 (Bottled 160810)
|
| Clinical testing›Ephedrine and related compounds |
(-)-Pseudoephedrine base |
D397 | 100 | 141 | 198 |
D397.2017.02 (Bottled 190220)
|
| Clinical testing›Ephedrine and related compounds |
(+)-Pseudoephedrine hydrochloride |
D775 | 50 | 110 | 154 |
D775b.2018.02 (Bottled 201117)
|
| Clinical testing›Opiates |
Acetylcodeine base |
D821 | 50 | 171 | 240 |
D821c.2020.01 (Bottled 150803)
|
| Clinical testing›Opiates |
Buprenorphine base |
D932 | 10 | 110 | 154 |
D932.2020.01 (Bottled 150915)
|
| Clinical testing›Opiates |
d3-Codeine base |
D673 | 1 | 141 | 198 |
D673
|
| Clinical testing›Opiates |
Codeine glucuronide |
D694 | 0.1 | 141 | 198 |
D694.2020.01 (Ampouled 130430)
|
| Clinical testing›Opiates |
d3-Codeine glucuronide |
D695 | 0.1 | 207 | 290 |
D695.2017.02 (Ampouled 140807)
|
| Clinical testing›Opiates |
Dihydrocodeine hydrogen tartrate |
D823 | 50 | 141 | 198 |
D823.2017.02
|
| Clinical testing›Opiates |
Hydrocodone |
D988 | 20 | 110 | 154 |
D988.2021.01 (Bottled 160831)
|
| Clinical testing›Opiates |
3-Monoacetylmorphine sulfamate |
D766 | 20 | 110 | 154 |
D766
|
| Clinical testing›Opiates |
6-Monoacetylmorphine base |
D777 | 20 | 110 | 154 |
D777c.2020.01
|
| Clinical testing›Opiates |
Morphine free base |
D408 | 50 | 141 | 198 |
D408e.2020.01 (Bottled 180627)
|
| Clinical testing›Opiates |
d3-Morphine base monohydrate |
D709 | 1 | 141 | 198 |
D709.2018.01 (Ampouled 091102b)
|
| Clinical testing›Opiates |
Morphine sulfate |
D925 | 50 | 141 | 198 |
D925.2020.01 (Bottled 190814)
|
| Clinical testing›Opiates |
Noscapine (Narcotine) base |
D831 | 50 | 141 | 198 |
D831
|
| Clinical testing›Opiates |
Noscapine hydrochloride |
D791 | 50 | 110 | 154 |
D791b.2019.01 (Bottled 171005)
|
| Clinical testing›Opiates |
Oxycodone |
D987 | 20 | 141 | 198 |
D987
|
| Clinical testing›Opiates |
Oxymorphone |
D1038 | 10 | 141 | 198 |
D1038.2020.01
|
| Clinical testing›Opiates |
Papaverine hydrochloride |
D750 | 50 | 110 | 154 |
D750b.2018.02 (Bottled 180629)
|
| Clinical testing›Opiates |
Pholcodine |
D539 | 20 | 141 | 198 |
D539b.2020.01
|
| Clinical testing›Opiates |
Thebaine base |
D731 | 20 | 110 | 154 |
D731b.2018.03
|
| Clinical testing›Miscellaneous |
Caffeine |
M724 | 50 | 141 | 198 |
M724c.2019.01
|
| Clinical testing›Miscellaneous |
Cannabidiol |
D512 | 25 | 110 | 154 |
D512b.2020.01 (Bottled151006)
, D512b.2021.01 (Bottled 210413)
|
| Clinical testing›Miscellaneous |
Ketamine hydrochloride |
D686 | 50 | 141 | 198 |
D686c.2018.02 (Bottled 150527)
|
| Clinical testing›Miscellaneous |
Meperidine hydrochloride (pethidine) |
D443 | 20 | 110 | 154 |
D443b.2021.01
|
| Clinical testing›Miscellaneous |
Methadone hydrochloride |
D425 | 20 | 110 | 154 |
D425b.2020.01 (Bottled 200402)
|
| Clinical testing›Miscellaneous |
Salbutamol |
M898 | 10 | 141 | 198 |
M898c.2018.03 (Bottled 190213)
|
| Clinical testing›Miscellaneous |
d3-Salbutamol |
D939 | 1 | 141 | 198 |
D939.2021.01 (Ampouled 120424)
|
| Clinical testing›Miscellaneous |
Salmeterol hydroxynaphthoate |
M904 | 50 | 141 | 198 |
M904.2018.03
|
| Clinical testing›Miscellaneous |
Selegiline hydrochloride |
D822 | 50 | 141 | 198 |
D822.2019.01
|
| Clinical testing›Synthetic cannabinoids |
AM1220 1-[(1-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)-indole |
D982 | 20 | 110 | 154 |
D982.2017.02
|
| Clinical testing›Synthetic cannabinoids |
AM2201 [1-(5-Fluoropentyl)-3-(1-napthoyl)-indole] |
D983 | 20 | 110 | 154 |
D983.2018.02
|
| Clinical testing›Synthetic cannabinoids |
N-Pentyl-3-(1-naphthoyl)indole |
D955 | 20 | 141 | 198 |
D955.2019.01
|
| Clinical testing›Synthetic cannabinoids |
JWH-210 [N-Pentyl-3-(4-ethyl-1-naphthoyl)indole] |
D984 | 5 | 110 | 154 |
D984.2018.02
|
| Clinical testing›Synthetic cannabinoids |
1-(5-Fluoro-pentyl)-3-(2,2,3,3- |
D1000 | 25 | 110 | 154 |
D1000.2019.02
|
| Clinical testing›Endogenous steroids and metabolites›Testosterone and metabolites |
Epitestosterone glucuronide sodium salt |
S035 | 1 | 110 | 154 |
S035.2020.01
|
| Clinical testing›Endogenous steroids and metabolites›Amphetamines |
(±)-4-Methylamphetamine hydrochloride |
D895 | 10 | 171 | 240 |
D895b.2018.02
|
*Production funded by the US Anti-Doping Agency.
†Production funded by the Australian Government through the Anti-Doping Research Program.
Clinical testing reference materials
Our RMs have demonstrated homogeneity and stability. We take all care in storing and handling these materials.
We have provided the currently valid certification where we can.
Certified reference materials
We produce certified reference materials (CRMs) with established metrological traceability to the SI unit for mass (kg). We report all purity values, stated as a mass fraction, with the associated uncertainty in the certificate of analysis.
Restrictions on issue
The steroid and steroid metabolite reference materials are generally available to laboratories accredited by the World Anti-doping Authority (WADA) or the International Olympic Committee (IOC).
If your laboratory doesn’t have WADA or IOC accreditation you must provide documented evidence, signed by the company manager, that you will not:
- use these materials for unethical purposes related to commercial human sports drug analysis
- provide the materials to other laboratories who may be engaged in this analysis
Ampouled materials
For each ampouled reference material the product information sheet or certificate of analysis will state the mass of analyte dispensed into each ampoule. For reference materials with certified reference material status we will report the mass of analyte with an associated uncertainty.
Goods and Services Tax for Australian customers
The prices quoted don’t include the Goods and Services Tax (GST). We will add GST— currently set at 10%—to our tax invoices and adjustment notes when required.
Delivery fee
Delivery and handling fees apply for all orders and vary with destination. We will provide the rates when you order.
To order
- Phone +61 2 9449 0191
- Email chemref@measurement.gov.au
- Write to us at Chemical Reference Materials Team, National Measurement Institute, GPO Box 2013, Canberra, ACT 2601, Australia
Read more
Find out more about our chemical reference materials
